In conclusion, the CD16-EGFR bispecific VHH reported here can trigger efficient lysis of EGFR expressing tumor cell lines and patient metastatic colorectal cancer cells and could represent a valid therapeutic strategy either alone or in combination with other NK cell-based therapeutic approaches, such as the anti-NKG2A monoclonal antibody monalizumab [73], or the adoptive transfer of expanded autologous or allogeneic NK cells. The gene discussed is FCGR3A; the disease is neoplasm.